Drug Profile
Research programme: small molecule therapeutics - Cornerstone Pharmaceuticals Inc
Alternative Names: CPI 1826; CPI 3220; CPI 618; CPI-3514; CPI-3517Latest Information Update: 19 May 2022
Price :
$50
*
At a glance
- Originator Cornerstone Pharmaceuticals
- Developer Cornerstone Pharmaceuticals Inc
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Haematological disorders
Most Recent Events
- 19 May 2022 Rafael Pharmaceuticals is now called Cornerstone Pharmaceuticals Inc
- 28 Jul 2021 No recent reports of development identified for preclinical development in Cancer in USA (PO, Controlled release)
- 28 Jul 2021 No recent reports of development identified for preclinical development in Haematological-disorders in USA (PO, Controlled release)